2023 annual financial data
Spyre Therapeutics 2023 Operating margin
Direct answer
Operating margin was -27,347.97%.
Operating income was -242,303,000 USD and net income was -338,790,000 USD.
Operating cash flow was -99,910,000 USD.
Get free Spyre Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 886,000 USD
- Operating income
- -242,303,000 USD
- Net income
- -338,790,000 USD
- Operating cash flow
- -99,910,000 USD